OICR News / Tag

WDR5

Browse news tagged WDR5.

Browse all news

Filters

Discover the latest news and insightsDiscover the latest news and insights

All Collaboration Commercialization Talent Technology

All Video Article

Tagged stories

TechnologyBlood cancers

A promising new way to stop proteins that drive cancer

A study led by OICR drug discovery researchers could pave the way for new treatment options for blood cancers. OICR researchers have discovered a new way to target proteins that drive leukemia and other cancers…

ArticleDec 13, 2024

TechnologyTreatment

Previously overlooked proteins are a potential source for a new class of cancer killing drugs

An open science project led by OICR’s Drug Discovery Program and the Structural Genomics Consortium is targeting WD-repeat proteins and generating exciting results. To unlock a new class of cancer-killing drugs, OICR researchers are looking…

ArticleAug 29, 2022

CommercializationBlood cancers

Op-ed in The Globe and Mail hails innovation strategy that resulted in record-breaking investment by Celgene

In a contribution to The Globe and Mail titled “For Innovation, open science means business”, E. Richard Gold and Max Morgan point to the recent investment by U.S. pharmaceutical giant Celgene into a potential treatment…

ArticleFeb 07, 2019

CollaborationTreatment

Open source cancer research

Doing things differently: The story behind the promising chemical probe developed by OICR and the Structural Genomics Consortium A recent collaboration between researchers at OICR and the Structural Genomics Consortium (SGC) used a new open-source…

ArticleFeb 12, 2016

CommercializationBlood cancers

FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia

First-in-class epigenetic modifiers discovered by OICR positioned for collaborative development TORONTO, Dec. 8, 2015 /CNW/ - Fight Against Cancer Innovation Trust ("FACIT") announced the acquisition of exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the…

ArticleDec 08, 2015

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

WDR5

Discover the latest news and insightsDiscover the latest news and insights

Tagged stories

A promising new way to stop proteins that drive cancer

Previously overlooked proteins are a potential source for a new class of cancer killing drugs

Op-ed in The Globe and Mail hails innovation strategy that resulted in record-breaking investment by Celgene

Cancer solved together — in your inbox

Open source cancer research

FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia